Carnegie acted as joint book runner in the secondary placing of Pronova BioPharma. Pronova BioPharma is a global leader in the research, development and manufacture of marine-originated omega-3 derived pharmaceutical products. May, 2009.
Healthcare
Secondary placing of 25.3 million shares in Pronova BioPharma ASA (NO) — NOK 467 million
May 2009